Musa Civak
Musa Civak has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Adalet Aypak
Department of Infectious Disease and Clinical Microbiology, Ankara Bilkent City Hospital, University of Health Sciences
2 shared publications - Ayse Kaya Kalem
Ankara Yildirim Beyazit University
2 shared publications - Emin Gemcioglu
Faculty of Medicine, Department of Internal Medicine, Health Sciences University, Ankara, Türkiye
2 shared publications - Emra Asfuroğlu Kalkan
Department of Internal Medicine, Ankara Bilkent City Hospital, 06800 Ankara, Türkiye
2 shared publications - Abdulsamet Erden
Division of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye
1 shared publication - Abdurrezzak Yılmaz
Department of Gastroenterology, Ankara Bilkent City Hospital, Ankara 06800, Turkey
1 shared publication
Latest Publications
- Open Access
- 10 September 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (3) , 219-228
Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?
It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05). In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.
- 10 September 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (3) , 219-228
Open AccessIs using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?
It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05). In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.
- Open Access
- 11 May 2021
- Published by Taylor & Francis in Future Virology
- Vol. 16 (5) , 353-367
Predictive Values of Biochemical Markers As Early Indicators for Severe COVID-19 Cases in Admission
Aim: COVID-19 is a pandemic that causes high morbidity and mortality, especially in severe patients. In this study, we aimed to search and explain the relationship between biochemical markers, whic... Graphical abstract
- 11 May 2021
- Published by Taylor & Francis in Future Virology
- Vol. 16 (5) , 353-367
Open AccessPredictive Values of Biochemical Markers As Early Indicators for Severe COVID-19 Cases in Admission
Aim: COVID-19 is a pandemic that causes high morbidity and mortality, especially in severe patients. In this study, we aimed to search and explain the relationship between biochemical markers, whic... Graphical abstract